Health

STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 15/11/2026, 15:06:24 UTC.

Briefings

The FDA rejected ivonescimab, a lung cancer treatment developed by Summit Therapeutics and Akeso, due to a lack of evidence that it extends patient survival. While the drug slowed cancer progression, it failed to improve overall survival rates, which is required for approval. This regulatory decision represents a setback for the U.S.-based biotech company, as the drug was not approved in China. The rejection occurred on November 15, 2026, following a letter from FDA reviewers.

Key points

• The FDA rejected ivonescimab because it did not extend patient survival, despite slowing cancer progression.
• Summit Therapeutics oversees development of the drug outside of China, where approval was not yet granted.

Context

The FDA rejected ivonescimab, a lung cancer treatment developed by Summit Therapeutics and Akeso, due to a lack of evidence that it extends patient survival. While the drug slowed cancer progression, it failed to improve overall survival rates, which is required for approval. This regulatory decision represents a setback for the U.S.-based biotech company, as the drug was not approved in China.

Limitations

The evidence is limited to a single FDA rejection letter dated November 15, 2026, from a public press release. No specific patient numbers, trial duration, or comparative survival data are provided. The source does not confirm whether the drug was previously approved in China or if any other approvals were granted.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 15/11/2026, 15:07:26 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeif2w3gs3b7pqtjlksazkicfxylt45bzc3o3po62szmxomilg6lvuq